<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675075</url>
  </required_header>
  <id_info>
    <org_study_id>N1902-P</org_study_id>
    <secondary_id>I21RX001902</secondary_id>
    <nct_id>NCT02675075</nct_id>
  </id_info>
  <brief_title>DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS</brief_title>
  <official_title>DESIPHER Speech Degradation as an Indicator of Physiological Degeneration in ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Florida Institute for Human and Machine Cognition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A disease called Amyotrophic lateral sclerosis (or ALS), which leads to difficulty&#xD;
      swallowing, breathing, and movement, has been found to be higher for those serving in the&#xD;
      military than in the general population. There are approximately 4,200 Veterans with ALS and&#xD;
      roughly 1,000 new cases each year. When doctors attempt to determine the degree to which an&#xD;
      ALS patient is suffering from the disease, they apply tests that are &quot;graded&quot; by experts.&#xD;
      However, this approach to testing patients may not be very accurate. Researchers aim to use a&#xD;
      system called DESIPHER to &quot;listen&quot; to ALS patients and find speech mistakes related to their&#xD;
      condition. Researchers believe that, by detecting different types of errors, DESIPHER serves&#xD;
      as a new kind of indicator of medical problems such as difficulty breathing or swallowing,&#xD;
      without human &quot;grading&quot;. This may also lead to a better system for automatically&#xD;
      understanding ALS patients' speech.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 2008, Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's Disease became a presumptively&#xD;
      compensable (service connected) disease as the Institute of Medicine (IOM) Committee stated&#xD;
      an association between the development of ALS and military service. According to the IOM&#xD;
      report, military service increases life risk of ALS by 1.5 fold. There are approximately&#xD;
      4,200 Veterans with ALS and roughly 1,000 new cases each year. At the Tampa VA, since 2007,&#xD;
      there has been a consistent rise in the number of Veterans diagnosed and treated with ALS.&#xD;
&#xD;
      Most physiological assessments that are commonly used to determine the functional status of&#xD;
      patients with ALS require trained clinical personnel to administer and interpret the results.&#xD;
      The investigators propose to use automatic speech understanding and machine learning software&#xD;
      (DESIPHER) to: identify speech pathologies and use them to predict other aspects of&#xD;
      physiological degeneration associated with ALS (e.g., respiratory difficulty or inability to&#xD;
      swallow), and ultimately improve speech recognition for those with speech impairments. The&#xD;
      investigators expect this to improve the ability to appropriately identify and intervene when&#xD;
      Veterans with ALS are at risk of serious adverse medical issues such as respiratory failure&#xD;
      and aspiration. The investigators postulate that analyzing the overall divergence of&#xD;
      (impaired) speech, from a &quot;normal&quot; baseline, will prove to be more robust and a better marker&#xD;
      for involvement than others that have been proposed.&#xD;
&#xD;
      Specific research questions to be addressed by this study are: (1) Is it possible to train a&#xD;
      speech recognition system to adapt to increasingly more frequent language/speech errors of&#xD;
      particular types, to produce an accurate textual transcript that would be readable by an ALS&#xD;
      patient's caregiver or physician? (2) Are specific changes in physiological functioning:&#xD;
      Forced Vital Capacity, tongue strength, speech velocity, weight (loss), aspiration risk, or&#xD;
      psychological distress, reflected in different types of language/speech errors associated&#xD;
      with ALS?&#xD;
&#xD;
      By understanding how speech functioning correlates with the degree to which other biophysical&#xD;
      functioning has degraded, it is possible to apply a new, non-invasive measure for assessing&#xD;
      the functionality of an ALS patient. In addition, the features associated with speech&#xD;
      degradation it is possible to adapt existing speech recognition software to a patient's&#xD;
      speech as it evolves over time, so that the quality of life for patients may be improved&#xD;
      through conversation with a computer.&#xD;
&#xD;
      Respiratory failure is the main cause of morbidity and mortality in ALS patients. The&#xD;
      investigators expect that the method of analyzing speech will present an excellent biomarker&#xD;
      for respiratory function, as there is an expected increase in pauses during speech due to the&#xD;
      necessity of increased frequency of respirations, a decrease in loudness, and decreased&#xD;
      overall velocity of speech. A second major cause of death is aspiration. As the articular&#xD;
      muscles decline, the investigators expect to note a decrease in the clarity of speech. Speech&#xD;
      involvement often precedes swallowing involvement in ALS; thus, the investigators expect that&#xD;
      increasing &quot;speech divergence&quot; will indicate potential aspiration risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percent of Expected Lung Force Vital Capacity</measure>
    <time_frame>Baseline, and every 3 months up to 24 months</time_frame>
    <description>Forced Vital Capacity (FVC) measures the ability of the lung to move air. The change in FVC was calculated from the initial time point to either the end of study (24 months) or to final visit due to either death or loss to followup.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Tongue Strength</measure>
    <time_frame>Baseline, 3 Month intervals up to 24 months, calculated from the initial time point to either the end of study (24 months) or to final visit due to either death or loss to followup</time_frame>
    <description>A physiological measurement of tongue muscle strength, in multiple directions. A force measured with Iowa Oral Performance Instrument (IOPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Speech - as Measured by Speech Divergence</measure>
    <time_frame>Baseline, 3 Month intervals up to 24 months, calculated from the initial time point to either the end of study (24 months) or to final visit due to either death or loss to followup</time_frame>
    <description>A measure looking at changes in vocal characteristics away from standard language. Speech Divergence is a novel calculated measure based on identifying changes to 13 characteristics of speech. The score can range from 0-13. Zero would represent normal speech, while 13 would be distorted speech along all parameters.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">34</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Veterans With ALS</arm_group_label>
    <description>This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A Cohort of Veteran diagnosed with ALS seen at the Tampa VA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Veterans will be diagnosed with ALS&#xD;
&#xD;
          -  Native speakers of U.S. English&#xD;
&#xD;
          -  Will have bulbar involvement identified during initial ALS inpatient evaluation&#xD;
&#xD;
          -  Forced vital capacity (FVC) of greater than 50% of the expected value for age&#xD;
&#xD;
          -  An Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) Score of 40 or&#xD;
             greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of dementia&#xD;
&#xD;
          -  FVC less than 50%&#xD;
&#xD;
          -  Inability to speak&#xD;
&#xD;
          -  Or inability to follow directions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel L. Phillips, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James A. Haley Veterans' Hospital, Tampa, FL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James A. Haley Veterans' Hospital, Tampa, FL</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <results_first_submitted>April 24, 2019</results_first_submitted>
  <results_first_submitted_qc>July 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2020</results_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Voice</keyword>
  <keyword>Voice Quality</keyword>
  <keyword>Total Lung Capacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02675075/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02675075/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the amyotrophic lateral sclerosis (ALS) Clinic at the James A. Haley Hospital from January 2016 to November 2017</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Veterans With ALS</title>
          <description>This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls</title>
          <description>Anonymous Controls who were not diagnosed with any nervous system diseases.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Veterans With ALS</title>
          <description>This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria. Veterans were at least 18 years old, and were diagnosed with ALS, and followed at the James A Haley VA Hospital</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls</title>
          <description>Healthy Controls were recruited to complete a one time vocal recording of the TIMIT and Ba repetition voice recordings.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="10.8"/>
                    <measurement group_id="B2" value="53.3" spread="11.2"/>
                    <measurement group_id="B3" value="57.8" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tongue Strength</title>
          <population>Healthy controls were only service as baseline for Vocal recordings to minimize burden on the subjects. Tongue strength was only collected for the ALS arm.</population>
          <units>KPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.6" spread="17.2"/>
                    <measurement group_id="B3" value="31.6" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lip Strength</title>
          <population>Healthy Controls were only serving as baseline for vocal recordings. Lip strength was only collected for the ALS ARM.</population>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.5" spread="9.0"/>
                    <measurement group_id="B3" value="15.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent of Predicted Forced Vital Capacity (FVC)</title>
          <population>Healthy controls only participated in vocal recording to minimize burden. This measurement was only taken for the ALS Arm of the study.</population>
          <units>Expected % Max FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.1" spread="21.9"/>
                    <measurement group_id="B3" value="69.1" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Speech Intelligence Test</title>
          <population>Healthy controls only participated in the Vocal recordings to minimize subject burden. This measurement was only collected for the ALS arm of the study.</population>
          <units>Percent words Intellegible</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.6" spread="4.5"/>
                    <measurement group_id="B3" value="98.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALS Functional Ratings Scale-Revised</title>
          <description>Standardized Outcome Measure: amyotrophic lateral sclerosis functional ratings scale-revised provides a physician-generated estimate of the patient's degree of functional impairment, which can be evaluated serially to objectively assess any response to treatment or progression of disease. There are 12 tasks, each task is rated from 0-4, producing a minimum score of 0 and maximum score of 48 with lower values representing a poorer outcome.</description>
          <population>Healthy controls only participated in the Vocal recordings to minimize subject burden. This measurement was only collected for the ALS arm of the study.</population>
          <units>units Standardized Outcome Measu</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="7.4"/>
                    <measurement group_id="B3" value="32.5" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Percent of Expected Lung Force Vital Capacity</title>
        <description>Forced Vital Capacity (FVC) measures the ability of the lung to move air. The change in FVC was calculated from the initial time point to either the end of study (24 months) or to final visit due to either death or loss to followup.</description>
        <time_frame>Baseline, and every 3 months up to 24 months</time_frame>
        <population>Data for this measure were not collected for healthy controls.</population>
        <group_list>
          <group group_id="O1">
            <title>Veterans With ALS</title>
            <description>This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>Anonymous Controls who were not diagnosed with any nervous system diseases.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent of Expected Lung Force Vital Capacity</title>
          <description>Forced Vital Capacity (FVC) measures the ability of the lung to move air. The change in FVC was calculated from the initial time point to either the end of study (24 months) or to final visit due to either death or loss to followup.</description>
          <population>Data for this measure were not collected for healthy controls.</population>
          <units>% Expected Forced Vital Capacity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tongue Strength</title>
        <description>A physiological measurement of tongue muscle strength, in multiple directions. A force measured with Iowa Oral Performance Instrument (IOPI)</description>
        <time_frame>Baseline, 3 Month intervals up to 24 months, calculated from the initial time point to either the end of study (24 months) or to final visit due to either death or loss to followup</time_frame>
        <population>Data for this measurement was only collected on the Veterans with ALS Arm. Data for this measure were not collected for healthy controls.</population>
        <group_list>
          <group group_id="O1">
            <title>Veterans With ALS</title>
            <description>This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria. Veterans were at least 18 years old, and were diagnosed with ALS, and followed at the James A Haley VA Hospital.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>Anonymous Controls who were not diagnosed with any nervous system diseases.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tongue Strength</title>
          <description>A physiological measurement of tongue muscle strength, in multiple directions. A force measured with Iowa Oral Performance Instrument (IOPI)</description>
          <population>Data for this measurement was only collected on the Veterans with ALS Arm. Data for this measure were not collected for healthy controls.</population>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.625" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Speech - as Measured by Speech Divergence</title>
        <description>A measure looking at changes in vocal characteristics away from standard language. Speech Divergence is a novel calculated measure based on identifying changes to 13 characteristics of speech. The score can range from 0-13. Zero would represent normal speech, while 13 would be distorted speech along all parameters.</description>
        <time_frame>Baseline, 3 Month intervals up to 24 months, calculated from the initial time point to either the end of study (24 months) or to final visit due to either death or loss to followup</time_frame>
        <population>Speech Divergence is a novel calculated measure for this study based on change in vocal characteristics of 13 characteristics. Speech Divergence was not collected for the Healthy Controls.</population>
        <group_list>
          <group group_id="O1">
            <title>Veterans With ALS</title>
            <description>This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria. Veterans were at least 18 years old, and were diagnosed with ALS, and followed at the James A Haley VA Hospital</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Speech - as Measured by Speech Divergence</title>
          <description>A measure looking at changes in vocal characteristics away from standard language. Speech Divergence is a novel calculated measure based on identifying changes to 13 characteristics of speech. The score can range from 0-13. Zero would represent normal speech, while 13 would be distorted speech along all parameters.</description>
          <population>Speech Divergence is a novel calculated measure for this study based on change in vocal characteristics of 13 characteristics. Speech Divergence was not collected for the Healthy Controls.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event Data was monitored from time of enrollment to end of study, loss to follow-up or death up to two years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Veterans With ALS</title>
          <description>This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.</description>
        </group>
        <group group_id="E2">
          <title>Healthy Controls</title>
          <description>Healthy Controls were enrolled for a one time vocal recording. There was no follow-up visits for healthy controls.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheostomy</sub_title>
                <description>Subject was withdrawn from study after having surgery for a tracheostomy due to oxygen insufficiency.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Death due to progression of ALS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study relied on the clinical team records to capture several variables. While there was clear protocols in place for clinicians, The ALSFRS-R and Speech Intelligibility Index both had missing data in the clinical record limiting analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sam Phillips</name_or_title>
      <organization>James A. Haley VA Hospital</organization>
      <phone>813 558 3995</phone>
      <email>samuel.phillips@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

